What clinicians should know about surrogate end points in hematologic malignancies

Area of Science:

• Hematology/Oncology
• Clinical Trials
• Biostatistics

Background:

• Surrogate end points are commonly used in hematology/oncology clinical trials.
• Unlike prognostic markers, surrogates predict the full treatment effect on true outcomes like overall survival.
• A clear understanding of surrogate end point validity is crucial for accurate research interpretation.

Purpose of the Study:

• To review the evidence supporting commonly used surrogate end points in hematology.
• To provide recommendations for the application and evaluation of surrogate end points in research and clinical practice.
• To bridge the gap between clinical practice and statistical expertise regarding surrogacy.

Main Methods:

• Literature review of statistical and clinical trial methodologies.
• Analysis of the evidential level for common surrogate end points in hematology.
• Synthesis of recommendations for researchers and clinicians.

Main Results:

• Discussion on the varying levels of evidence for different surrogate end points.
• Identification of best practices for surrogate end point selection and validation.
• Highlighting the importance of statistical rigor in surrogate end point research.

Conclusions:

• Surrogate end points are valuable tools in clinical trials when appropriately validated.
• Clinicians and researchers should be aware of the evidence supporting specific surrogates.
• Adherence to methodological recommendations enhances the reliability of surrogate end point findings.